Compound ID | 3653

Update compound information

LTV17

Synonym(s): LTV-17  |  LTV 17  |  lactivicin derivative 17

Class: Small molecule antibacterial agent

Agent Type: Semisynthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-negative
Mechanism of action: Cell wall synthesis inhibitor. Non-beta lactam PBP inhibitor
Target Pathogen: Active against Stenotrophomonas maltophilia, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Description: Semisynthetic compound with core scaffold from natural product lactivicin containing a siderophore; a phthalimide-conjugated sideromimic antibiotic; shows reduced susceptibility to beta-lactamases; allows siderophore receptor-mediated drug uptake
Institute where first reported: Pfizer; Fedora Pharmaceuticals Inc.
Year first mentioned: 2014
Development status: Experimental
Chemical structure(s):
Click here for structure editor
Molecular weight:
Iso. SMILES: CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2CON(C2=O)C3(C[C@@H](C(=O)O3)N4C(=O)C5=CC(=C(C=C5C4=O)O)O)C(=O)O
InChI Key: JIGNDUNBKKQBKB-OIANMIDYSA-N
Can. SMILES: CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2CON(C2=O)C3(C[C@@H](C(=O)O3)N4C(=O)C5=C(C=C(C(=C5)O)O)C4=O)C(=O)O
InChI: InChI=1S/C25H22N6O14S/c1-24(2,21(39)40)45-29-15(11-7-46-23(26)28-11)16(34)27-10-6-43-31(19(10)37)25(22(41)42)5-12(20(38)44-25)30-17(35)8-3-13(32)14(33)4-9(8)18(30)36/h3-4,7,10,12,32-33H,5-6H2,1-2H3,(H2,26,28)(H,27,34)(H,39,40)(H,41,42)/b29-15-/t10-,12-,25?/m0/s1
External links:
Structure link: https://pubchem.ncbi.nlm.nih.gov/compound/90656109
Guide to Pharmacology: LTV17
Citations:
  • https://journals.asm.org/doi/10.1128/aac.00371-16
  • https://pubs.acs.org/doi/full/10.1021/jm500219c?getft_integrator=asm&utm_source=asm

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.